Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis or renal limited vasculitis~* Male and female subjects, aged at least 18 years, with new or relapsed AAV where treatment with cyclophosphamide or rituximab would be required~* Use of adequate contraception during, and for at least the three months after, any administration of study medication is required~* Positive indirect immunofluorescence (IIF) test for P-ANCA or C-ANCA, or positive ELISA test for anti-proteinase-3 (PR3) or anti-myeloperoxidase (MPO) at screening~* Have at least one major item, or at least 3 other items, or at least 2 renal items on the Birmingham Vasculitis Activity Score (BVAS) version 3~* Estimated glomerular filtration rate (eGFR) ≥ 20 mL per minute~Exclusion Criteria:~* Severe disease as determined by rapidly progressive glomerulonephritis, alveolar hemorrhage, hemoptysis, rapid-onset mononeuritis multiplex or central nervous system involvement~* Any other multi-system autoimmune disease~* Medical history of coagulopathy or bleeding disorder~* Received cyclophosphamide within 12 weeks prior to screening; if on azathioprine, mycophenolate mofetil, or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the cyclophosphamide or rituximab dose on Day 1~* Received intravenous corticosteroids, \>3000 mg methylprednisolone equivalent, within 12 weeks prior to screening~* Received an oral daily dose of a corticosteroid of more than 10 mg prednisone-equivalent for more than 6 weeks continuously prior to the screening visit~* Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks provided B cell reconstitution has occurred; received anti-tumor necrosis factor (TNF) treatment, abatacept, alemtuzumab, intravenous immunoglobulin (IVIg), belimumab, tocilizumab, or plasma exchange within 12 weeks prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CCX168 low dose plus standard of care (Type: ACTIVE_COMPARATOR): Capsule, 10 mg, twice daily + standard of care for 12 weeks
- CCX168 high dose plus standard of care (Type: ACTIVE_COMPARATOR): Capsule, 30 mg, twice daily + standard of care for 12 weeks
- Placebo, twice daily + standard of care (Type: PLACEBO_COMPARATOR): Capsule, placebo, twice daily + standard of care for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).